Protagonist TherapeuticsPTGX
PTGX
About: Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Employees: 126
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
20% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 75
13% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 40
0.53% more ownership
Funds ownership: 105.63% [Q3] → 106.16% (+0.53%) [Q4]
0% more funds holding
Funds holding: 238 [Q3] → 239 (+1) [Q4]
8% less call options, than puts
Call options by funds: $8.73M | Put options by funds: $9.52M
13% less capital invested
Capital invested by funds: $2.8B [Q3] → $2.44B (-$358M) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$38
32%
downside
Avg. target
$63
13%
upside
High target
$80
43%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Truist Securities Srikripa Devarakonda 40% 1-year accuracy 14 / 35 met price target | 36%upside $76 | Buy Maintained | 11 Mar 2025 |
BMO Capital Etzer Darout 31% 1-year accuracy 11 / 36 met price target | 29%upside $72 | Outperform Reiterated | 11 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 25% 1-year accuracy 45 / 180 met price target | 43%upside $80 | Buy Maintained | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 31% 1-year accuracy 23 / 75 met price target | 9%upside $61 | Market Outperform Reiterated | 10 Mar 2025 |
JP Morgan Brian Cheng 18% 1-year accuracy 3 / 17 met price target | 2%upside $57 | Overweight Maintained | 4 Mar 2025 |
Financial journalist opinion
Based on 9 articles about PTGX published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why
Protagonist Therapeutics (PTGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Seeking Alpha
1 day ago
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc. achieved primary endpoint in a phase 3 VERIFY study using rusfertide in polycythemia vera and the phase 2b ANTHEM-UC study using icotrokinra in ulcerative colitis. Icotrokinra, a first-in-class IL-23 receptor agonist, shows promise in treating ulcerative colitis and plaque psoriasis, potentially shifting treatment paradigms in both of these indications. Financially stable with $559.2 million in cash and recent milestone payments, Protagonist can fund operations through 2028, reducing financial risk.
Positive
Zacks Investment Research
1 day ago
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
Positive
Schwab Network
2 days ago
Overlooked Stock: PTGX
Protagonist Therapeutics (PTGX) rallied 45% after its latest drug trial to treat people with active ulcerative colitis saw success. George Tsilis says there's more positive catalysts behind the stock, particularly its cash pile.
Positive
Investors Business Daily
3 days ago
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
Protagonist Therapeutics broke out Monday after the company's drug topped its rival from Bristol in a psoriasis study. The post Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out appeared first on Investor's Business Daily.
Positive
Benzinga
3 days ago
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra (JNJ-2113) in adults with moderately to severely active ulcerative colitis (UC).
Neutral
Business Wire
1 week ago
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first.
Positive
Zacks Investment Research
2 weeks ago
Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $1.98 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.44 per share a year ago.
Neutral
Accesswire
2 weeks ago
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025 PN-881, a potential best-in-class oral IL-17 receptor antagonist peptide nominated as a development candidate in Q4 2024 Topline results for rusfertide Phase 3 VERIFY clinical trial in polycythemia vera expected in March 2025 Topline results for icotrokinra Phase 2b ANTHEM clinical trial in moderate to severe ulcerative colitis expected in March 2025 Cash, cash equivalents, and marketable securities of $559.2 million as of December 31, 2024, combined with $165.0 million milestone payment, anticipated to provide cash runway through at least end of 2028 NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. "Protagonist is quickly approaching multiple late-stage transformational events expected in the first quarter of this year, including the topline results from the VERIFY Phase 3 study of rusfertide in polycythemia vera and from the ANTHEM Phase 2b ulcerative colitis study of icotrokinra," said Dinesh V.
Positive
Seeking Alpha
1 month ago
Protagonist: Rusfertide PV Data Q1 2025 Isn't The Only 2025 Catalyst On Deck
Positive results achieved from both ICONIC studies using JNJ-2113 for the treatment of patients with moderate-to-severe plaque psoriasis; Superiority study is data expected in Q2 of 2025. Topline results from the phase 3 VERIFY study, using rusfertide for the treatment of patients with polycythemia vera, expected in Q1 of 2025. The global Polycythemia vera market size is expected to grow to $2.03 billion by 2032.
Charts implemented using Lightweight Charts™